Investors who lost money on Moderna, Inc. (“Moderna” or the “Company”) stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP (“Glancy”) today announced a securities fraud investigation on behalf of Moderna, Inc. (NASDAQ: MRNA) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 22, 2026 disclosure regarding Moderna, Inc.
Investors who lost money on Moderna, Inc. securities can submit their Moderna, Inc. loss information to learn about potentially pursuing claims to recover their losses.
Key facts in the Moderna, Inc. investigation
- Disclosure date: October 22, 2026
- Stock price decline: $56.71 per share, or 23.07%
What happened?
On October 22, 2026, an early release of closely watched clinical trial results for Moderna and Merck’s joint experimental cancer vaccine appeared on medical news website Oncology Central but were taken down shortly afterward. According to the briefly published report, combining the Moderna and Merck’s personalized mRNA cancer vaccine with Merck’s blockbuster immunotherapy Keytruda reduced the risk of melanoma returning or death by 42% compared with Keytruda alone.
On this news, Moderna stock fell as much as $56.71 or 23.07%, during intraday trading on October 22, 2026.
“The price of Moderna, Inc. shares fell 23.07% following the October 22, 2026 disclosure that Oncology Central briefly published clinical trial results reporting that Moderna and Merck’s personalized mRNA cancer vaccine combined with Keytruda reduced the risk of melanoma returning or death by 42% compared with Keytruda alone. Investors who suffered losses deserve to know whether they were given complete and accurate information prior to the disclosure, and our investigation seeks to answer that question,” said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.
What’s the next step?
Glancy is investigating potential claims on behalf of Moderna, Inc. investors. Investors who lost money can contact Glancy about the Moderna, Inc. investigation, email shareholders@glancylaw.com, or call 310-201-9150 (toll-free: 888-773-9224).
Frequently Asked Questions
Who is eligible? Investors who bought Moderna, Inc. securities and lost money may have claims, and can contact Glancy to learn whether they are affected by the Moderna, Inc. investigation.
What is a securities fraud investigation? In the Moderna, Inc. investigation, Glancy is reviewing whether the Company or its executives may have made false or misleading statements to investors in violation of the federal securities laws.
Has a lawsuit been filed? This release announces Glancy’s investigation, not a lawsuit. If a securities class action is later filed against Moderna, Inc., investors may have the opportunity to seek appointment as lead plaintiff.
Does it cost anything to contact Glancy or participate in this investigation? Glancy represents Moderna, Inc. investors on a contingency fee basis, so investors pay no attorneys’ fees out of pocket. Any attorneys’ fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.
Why work with Glancy on the Moderna, Inc. investigation? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Moderna, Inc. investigation. Prior results do not guarantee a similar outcome.
Whistleblower notice
Persons with non-public information about Moderna, Inc. should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information that leads to a successful SEC enforcement action may receive awards of 10 to 30 percent of the sanctions collected, when those sanctions exceed $1 million. For more information, contact Charles H. Linehan at 310-201-9150 or 888-773-9224, or email shareholders@glancylaw.com.
About Glancy Prongay Wolke & Rotter LLP
Glancy was named one of Law360’s Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.
Glancy’s successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.
Prior results do not guarantee a similar outcome.
Related links
- Moderna, Inc. investigation page, Glancy Prongay Wolke & Rotter LLP
- Moderna, Inc. SEC filings index, EDGAR
- SEC Whistleblower Program
- Glancy Prongay Wolke & Rotter LLP
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261023723851/en/
Media gallery
